Anti-inflammatory response to curcumin supplementation in chronic kidney disease and hemodialysis patients: A systematic review and meta-analysis

Document Type : Review Article


1 Department of Pediatric Nephrology, Emam Hossein Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Modeling in Health Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

3 Department of Pediatric Clinical Pharmacology, Department of Pharmacology & Toxicology, Wright State University Boonshoft School of Medicine, Dayton Children's Hospital, One Children's Plaza, Dayton, Ohio, USA


Objective: This study was designed to determine the association curcumin has on pro-inflammatory biomarkers in patients with chronic kidney disease (CKD (and in those receiving hemodialysis (HD).
Materials and Methods: This meta-analysis was undertaken following PRISMA guidelines. An extensive systematic review was undertaken until 10/11/2021 using PubMed, Web of Science (ISI), and Scopus databases. The standardized mean difference (SMD) and 95% confidence intervals (CI) were used to estimate the overall effect size of curcumin on serum high-sensitivity C-reactive protein (hs-CRP), and pro-inflammatory cytokines including interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) in patients with CKD and those receiving HD.
Results: Overall, ten randomized controlled trials (RCTs) comprising 523 patients were incorporated into the systematic review and meta-analysis. The results showed that when compared with control groups, there was no significant effect observed linking curcumin and IL-6 (SMD = 0.24%, 95% CI = -0.14 to 0.62, p = 0.221), TNF-α (SMD = 0.11%, 95% CI = -0.19 to 0.40, p = 0.480) or hs-CRP (SMD = -0.17%, 95% CI = -0.36 to 0.03, p = 0.093). The analysis determined no publication bias related to the influence of curcumin on IL-6, TNF-α or acute phase reactant, hs-CRP. The Egger’s and Begg’s test results were not statistically significant (p˃0.20).
Conclusion: In patients with CKD and those receiving HD, the use of curcumin supplementation has no statistically significant effect on the anti-inflammatory biomarkers reviewed in this study.


Alvarenga L, Leal VO, Borges NA, Aguiar
ASd, Faxén-Irving G, Stenvinkel P,
Lindholm B, Mafra D. 2018. Curcumin -
A promising nutritional strategy for
chronic kidney disease patients. J Funct
Foods, 40: 715-721.
Alvarenga L, Salarolli R, Cardozo L, Santos
RS, de Brito JS, Kemp JA, Reis D, de
Paiva BR, Stenvinkel P, Lindholm B,
Fouque D, Mafra D. 2020. Impact of
curcumin supplementation on expression
of inflammatory transcription factors in
hemodialysis patients: A pilot randomized,
double-blind, controlled study. Clin Nutr,
39: 3594-3600.
Ammirati AL. 2020. Chronic Kidney Disease.
Rev Assoc Med Bras (1992), 66Suppl 1:
Bagherniya M, Soleimani D, Rouhani MH,
Askari G, Sathyapalan T, Sahebkar A.
2021. The use of curcumin for the
treatment of renal disorders: a systematic
review of randomized controlled trials.
Adv Exp Med Biol, 1291: 327-343.
Bartaula B, Subedi M, Kumar MM, Shrestha
M, Bichha N, Mudbhari B. 2019.
Spectrum of complications in chronic
kidney disease patients undergoing
maintenance hemodialysis: An experience
of a tertiary care center in Nepal. Saudi J
Kidney Dis Transpl, 30: 208-214.
Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel
P. 2008. Cytokine dysregulation in chronic
kidney disease: how can we treat it? Blood
Purif, 26: 291-299.
Chan WH, Wu HY, Chang WH. 2006. Dosage
effects of curcumin on cell death types in a
human osteoblast cell line. Food Chem
Toxicol, 44: 1362-1371.
GBD Chronic Kidney Disease Collaboration.
2020. Global, regional, and national
burden of chronic kidney disease, 1990-
2017: a systematic analysis for the global
burden of disease study 2017. Lancet, 395:
Corsonello A, Freiberger E, Lattanzio F. 2020.
The screening for chronic kidney disease
among older people across Europe
(SCOPE) project: findings from crosssectional analysis. BMC Geriatr, 20: 316-
Crewe C, An YA, Scherer PE. 2017. The
ominous triad of adipose tissue
dysfunction: inflammation, fibrosis, and
impaired angiogenesis. J Clin Invest, 127:
Ferguson JJA, Abbott KA, Garg ML. 2021.
Anti-inflammatory effects of oral
supplementation with curcumin: a
systematic review and meta-analysis of
randomized controlled trials. Nutr Rev, 79:
Gorabi AM, Razi B, Aslani S, Abbasifard M,
Imani D, Sathyapalan T, Sahebkar A.
2021. Effect of curcumin on
proinflammatory cytokines: A metaanalysis of randomized controlled trials.
Cytokine, 143: 155541.
Gupta SC, Patchva S, Aggarwal BB. 2013.
Therapeutic roles of curcumin: lessons
learned from clinical trials. AAPS J, 15:
Haroyan A, Mukuchyan V, Mkrtchyan N,
Minasyan N, Gasparyan S, Sargsyan A,
Narimanyan M, Hovhannisyan A. 2018.
Efficacy and safety of curcumin and its
combination with boswellic acid in
osteoarthritis: a comparative, randomized,
double-blind, placebo-controlled study.
BMC Complement Altern Med, 18: 7.
Hasan M, Sutradhar I, Gupta RD, Sarker M.
2018. Prevalence of chronic kidney
disease in South Asia: a systematic review.
BMC Nephrol, 19: 291-291.
Jiménez-Osorio AS, García-Niño WR,
González-Reyes S, Álvarez-Mejía AE,
Guerra-León S, Salazar-Segovia J, Falcón
I, de Oca-Solano HM, Madero M,
Pedraza-Chaverri J. 2016. The effect of
dietary supplementation with curcumin on
redox status and Nrf2 activation in patients
with nondiabetic or diabetic proteinuric
chronic kidney disease: a pilot study. J Ren
Nutr, 26: 237-244.
Kabodan MH, Kooshki A, Rad M, Tabarraie Y,
Sharifipour F. 2018. Investigating the
effect of curcumin supplement
consumption on systematic inflammation
in hemodialysis patients. Int J Life Sci
Pharma Res, 8: 39-47.
Khajehdehi P, Pakfetrat M, Javidnia K, Azad F,
Malekmakan L, Nasab MH,
Dehghanzadeh G. 2011. Oral
supplementation of turmeric attenuates
proteinuria, transforming growth factor-β
and interleukin-8 levels in patients with
overt type 2 diabetic nephropathy: a
randomized, double-blind and placebo-
Anti-inflammatory response to curcumin hemodialysis
AJP, Vol. 12, No. 6, Nov-Dec 2022 587
controlled study. Scand J Urol Nephrol,
45: 365-370.
Kotha RR, Luthria DL. 2019. Curcumin:
biological, pharmaceutical, nutraceutical,
and analytical aspects. Molecules, 24:
Kunnumakkara AB, Bordoloi D, Padmavathi
G, Monisha J, Roy NK, Prasad S,
Aggarwal BB. 2017. Curcumin, the golden
nutraceutical: multitargeting for multiple
chronic diseases. Br J Pharmacol, 174:
Marton LT, Barbalho SM, Sloan KP, Sloan LA,
Goulart RA, Araújo AC, Bechara MD.
2022. Curcumin, autoimmune and
inflammatory diseases: going beyond
conventional therapy – a systematic
review. Crit Rev Food Sci Nutr, 62: 2140-
Memarzia A, Khazdair MR, Behrouz S,
Gholamnezhad Z, Jafarnezhad M, Saadat
S, Boskabady MH. 2021. Experimental
and clinical reports on anti-inflammatory,
antioxidant, and immunomodulatory
effects of Curcuma longa and curcumin, an
updated and comprehensive review.
Biofactors, 47: 311-350.
Mihai S, Codrici E, Popescu ID, Enciu AM,
Albulescu L, Necula LG, Mambet C,
Anton G, Tanase C. 2018. Inflammationrelated mechanisms in chronic kidney
disease prediction, progression, and
outcome. J Immunol Res, 2018: 2180373.
Miller PD. 2014. Chronic kidney disease and
osteoporosis: evaluation and management.
Bonekey Rep, 3: 542-542.
Mohammad pour A, Dastani M, Salari R,
Radbin S, Mehri S, Ghorbani M, Karimani
A, Salari M. 2019. Curcumin effects on
myeloperoxidase, interleukin-18 and
matrix metalloproteinase-9 inflammatory
biomarkers in patients with unstable
angina: A randomized clinical trial.
Avicenna J Phytomed, 9: 428-435.
Moreillon JJ, Bowden RG, Deike E, Griggs J,
Wilson R, Shelmadine B, Cooke M,
Beaujean A. 2013. The use of an antiinflammatory supplement in patients with
chronic kidney disease. J Complement
Integr Med, 10: 1-10.
Moreno Velásquez I, Tribaldos Causadias M,
Valdés R, Gómez B, Motta J, Cuero C,
Herrera-Ballesteros V. 2019. End-stage
renal disease-financial costs and years of
life lost in Panama: a cost-analysis study.
BMJ Open, 9: e027229.
Najafi H, Changizi Ashtiyani S, Sayedzadeh
SA, Mohamadi yarijani Z, Fakhri S. 2015.
Therapeutic effects of curcumin on the
functional disturbances and oxidative
stress induced by renal
ischemia/reperfusion in rats. Avicenna J
Phytomed, 5: 576-586.
Pakfetrat M, Akmali M, Malekmakan L,
Dabaghimanesh M, Khorsand M. 2015.
Role of turmeric in oxidative modulation
in end-stage renal disease patients.
Hemodial Int, 19: 124-131.
Pakfetrat M, Basiri F, Malekmakan L, Roozbeh
J. 2014. Effects of turmeric on uremic
pruritus in end stage renal disease patients:
a double-blind randomized clinical trial. J
Nephrol, 27: 203-207.
Pretto CR, Winkelmann ER, Hildebrandt LM,
Barbosa DA, Colet CF, Stumm EMF.
2020. Quality of life of chronic kidney
patients on hemodialysis and related
factors. Rev Lat Am Enfermagem, 28:
Rahban M, Habibi-Rezaei M, Mazaheri M,
Saso L, Moosavi-Movahedi AA. 2020.
Anti-viral potential and modulation of
Nrf2 by curcumin: pharmacological
implications. Antioxidants, 9: 1228.
Rodrigues HCN, Martins TFP, Santana N,
Braga CC, Silva MAC, Cunha LCD,
Sugizaki CSA, Freitas A, Costa NA,
Peixoto M. 2021. Antioxidant and antiinflammatory response to curcumin
supplementation in hemodialysis patients:
A randomized, double-blind, placebocontrolled clinical trial. Clin Nutr ESPEN,
44: 136-142.
Salarolli RT, Alvarenga L, Cardozo L, Teixeira
KTR, de SGML, Lima JD, Rodrigues SD,
Nakao LS, Fouque D, Mafra D. 2021. Can
curcumin supplementation reduce plasma
levels of gut-derived uremic toxins in
hemodialysis patients? A pilot
randomized, double-blind, controlled
study. Int Urol Nephrol, 53: 1231-1238.
Samadian F, Dalili N, Poor-Reza Gholi F,
Fattah M, Malih N, Nafar M, Firoozan A,
Ahmadpoor P, Samavat S, Ziaie S. 2017.
Evaluation of curcumin's effect on
inflammation in hemodialysis patients.
Clin Nutr ESPEN, 22: 19-23.
Shafabakhsh R, Asemi Z, Reiner Z, Soleimani
A, Aghadavod E, Bahmani F. 2020. The
effects of nano-curcumin on metabolic
Emami et al.
AJP, Vol. 12, No. 6, Nov-Dec 2022 588
status in patients with diabetes on
hemodialysis, a randomized, double blind,
placebo-controlled trial. Iran J Kidney Dis,
14: 290-299.
Sharifi-Rad J, Rayess YE, Rizk AA, Sadaka C,
Zgheib R, Zam W, Sestito S, Rapposelli S,
Neffe-Skocińska K, Zielińska D, Salehi B,
Setzer WN, Dosoky NS, Taheri Y, El
Beyrouthy M, Martorell M, Ostrander EA,
Suleria HAR, Cho WC, Maroyi A, Martins
N. 2020. Turmeric and its major
compound curcumin on health: bioactive
effects and safety profiles for food,
pharmaceutical, biotechnological and
medicinal applications. Front Pharmacol,
11: 01021.
Shelmadine BD, Bowden RG, Moreillon JJ,
Cooke MB, Yang P, Deike E, Griggs JO,
Wilson RL. 2017. A pilot study to examine
the effects of an anti-inflammatory
supplement on eicosanoid derivatives in
patients with chronic kidney disease. J
Altern Complement Med, 23: 632-638.
Stohs SJ, Chen O, Ray SD, Ji J, Bucci LR,
Preuss HG. 2020. Highly bioavailable
forms of curcumin and promising avenues
for curcumin-based research and
application: a review. Molecules, 25:
Subeesh VK, Abraham R, Satya Sai MV,
Koonisetty KS. 2020. Evaluation of
prescribing practices and drug-related
problems in chronic kidney disease
patients: A cross-sectional study. Perspect
Clin Res, 11: 70-74.
Tinti F, Lai S, Noce A, Rotondi S, Marrone G,
Mazzaferro S, Di Daniele N, Mitterhofer
AP. 2021. Chronic kidney disease as a
systemic inflammatory syndrome: update
on mechanisms involved and potential
treatment. Life, 11: 419.
Vafadar-Afshar G, Rasmi Y, Yaghmaei P,
Khadem-Ansari MH, Makhdoomi K,
Rasouli J. 2021. The effects of
nanocurcumin supplementation on
inflammation in hemodialysis patients: A
randomized controlled trial. Hemodial Int,
25: 232-239.
Vafadar Afshar G, Rasmi Y, Yaghmaei P,
Khadem-Ansari MH, Makhdomii K,
Rasooli J. 2020. The effects of nanocurcumin supplementation on serum Level
of hs-CRP, adhesion molecules, and lipid
profiles in hemodialysis patients, a
randomized controlled clinical trial. Iran J
Kidney Dis, 14: 52-61.
Vanaie A, Shahidi S, Iraj B, Siadat ZD,
Kabirzade M, Shakiba F, Mohammadi M,
Parvizian H. 2019. Curcumin as a major
active component of turmeric attenuates
proteinuria in patients with overt diabetic
nephropathy. J Res Med Sci, 24: 77.
Welz AN, Emberger-Klein A, Menrad K. 2018.
Why people use herbal medicine: insights
from a focus-group study in Germany.
BMC Complement Altern Med, 18: 92.
White CM, Pasupuleti V, Roman YM, Li Y,
Hernandez AV. 2019. Oral
turmeric/curcumin effects on
inflammatory markers in chronic
inflammatory diseases: A systematic
review and meta-analysis of randomized
controlled trials. Pharmacol Res, 146:
Whittaker CF, Miklich MA, Patel RS, Fink JC.
2018. Medication safety principles and
practice in CKD. Clin J Am Soc Nephrol,
13: 1738-1746.
Xu G, Gu Y, Yan N, Li Y, Sun L, Li B. 2021.
Curcumin functions as an antiinflammatory and antioxidant agent on
arsenic-induced hepatic and kidney injury
by inhibiting MAPKs/NF-κB and
activating Nrf2 pathways. Environ
Toxicol, 36: 2161-2173.
Yang H, Xu W, Zhou Z, Liu J, Li X, Chen L,
Weng J, Yu Z. 2015. Curcumin attenuates
urinary excretion of albumin in type II
diabetic patients with enhancing nuclear
factor erythroid-derived 2-like 2 (Nrf2)
system and repressing inflammatory
signaling efficacies. Exp Clin Endocrinol
Diabetes, 123: 360-367.
Yuan H, Ma Q, Ye L, Piao G. 2016. The
traditional medicine and modern medicine
from natural products. Molecules, 21: 559.